DigestRedComo funciona
Red
/
Empresas
En
No verificado

Enterome

Sobre qué escribimos

Anuncios brevesBiotecnologíaEventosFarmacéuticaMedicina Salud Bienestar

8 Comunicados de prensa

Ver todos los comunicados de prensa
01/12/2025
Biotecnología
Medicina Salud Bienestar
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
Fuente
Enterome
Editor
GLOBENEWSWIRE
1.00
0
12/11/2025
Biotecnología
Medicina Salud Bienestar
Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting
Fuente
Enterome
Editor
GLOBENEWSWIRE
1.00
0
15/10/2025
Biotecnología
Medicina Salud Bienestar
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
Fuente
Enterome
Editor
GLOBENEWSWIRE
1.00
0
22/06/2025
Biotecnología
Anuncios breves
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
Fuente
Enterome
Editor
GLOBENEWSWIRE
1.00
0
11/06/2025
Biotecnología
Anuncios breves
Finanzas
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
Fuente
Enterome
Editor
GLOBENEWSWIRE
1.00
0
02/06/2025
Biotecnología
Medicina Salud Bienestar
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
Fuente
Enterome
Editor
GLOBENEWSWIRE
1.00
0
29/05/2025
Biotecnología
Medicina Salud Bienestar
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
Fuente
Enterome
Editor
GLOBENEWSWIRE
1.00
0
13/11/2024
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Web y redes sociales
Enterome to Host Webinar on New Clinical Data From the Ongoing Phase 1/2 ‘SIDNEY’ Trial of Lead Programme, EO2463
Fuente
Enterome
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0